Transasia Bio-Medicals Ltd., India’s leading IVD Company today announced that it will soon be foraying into the Rs. 300 crore Indian molecular diagnostics space. It unveiled the MX 16, a fully automated nucleic acid extractor, at the 50th Union World Conference on Lung Health and TB in Hyderabad. The MX 16 has been developed by Erba Molecular, a UK subsidiary of the Transasia-Erba group.
The new system will offer an easy-to-use and lower priced molecular TB test in India, with the goal of replacing traditional smear microscopy.
The system will be particularly beneficial to India, which has the highest burden of TB and drug-resistant TB: one in four TB patient globally are in India. Also, 89% of affected individuals in India are in the productive age group 15-69, which makes it a critical national health issue to be addressed.
Though TB incidence in India has been declining at 1.7% annually since 2016, it is estimated that it needs to fall by 10% annually to reach the Government’s 2025 goal of ending TB in the country. Currently a significant number of TB patients remain undiagnosed for long and out of those diagnosed, only 65% of cases in India are treated.
About Transasia Bio-Medicals Ltd.:
Founded in 1979, Transasia Bio-Medicals Ltd., India’s Leading In-vitro Diagnostic Company offers products and solutions in Biochemistry, Hematology, Coagulation, ESR, Immunology, Urinalysis, Critical Care, Diabetes Management, Microbiology and Molecular Diagnostics. It provides doctors and patients with reliable, affordable and innovative diagnostic systems, with 70,000+ installations across India. It has a network of 300 service engineers, 400+ sales and marketing team, 24 zonal offices and 350+ distributors. It is the first Indian company to manufacture and export blood analyzers and reagents, in the 1990s.
Transasia’s indigenous research has resulted in development of state of the art, ‘Make in India’ products and technologies, enabling its products to be among the best in the world. All along its journey spanning four decades, Transasia has been recognized for its commitment to healthcare. It has been conferred ‘The Economic Times Best Brands 2019’ award, ‘India Medical Device – Export Company of the Year’ and the ‘Global Growth Company-2014’ award by the World Economic Forum among many others.
Headquartered in Mumbai, Transasia is a part of the Transasia-Erba group which has footprint across USA, UK, Germany, Czech Republic, France, Italy, Russia and Turkey through various acquisitions and serves millions across 100 countries. Its’ production sites in India, Czech Republic and US and R&D centres in France, UK, India and Czech Republic form a hub for world class, indigenous research and manufacturing. Do visit www.erbamannheim.com for details.